New immuno-oncology personalized therapy approaches

Genome & Company is developing a microbiome-based add-on therapy for programmed cell death 1/programmed cell death 1 ligand 1 inhibitors. It is also developing novel targeted immune checkpoint inhibitors, and believes these two approaches could be combined for personalized therapy.

Sep 12, 2019
0
0
Page of

Genome and Company

Genome & Company which is researching and developing dietary supplements, cosmeceuticals, and new drugs utilizing microbiome, pursues people’s happy life. We have been studying microbes and probiotics which can be applied to obesity, diabetes, acne, atopic dermatitis, and cancer complementary therapies with the vision of becoming the Asian Flagship Company of the Human Microbiome Industry and the objective of market driven product development by 2018. We seek to identify what causes diseases, integrating the functional mechanism using a simulator of the human colon microbial ecosystem and multi-omics profiling through Next generation sequencing. Currently, Genome & Company’s technology and capabilities are evidenced by partnerships with Major hospitals, Schools, Research Institutes and Governments; and it’s our privilege to be able to focus exclusively on research & development thanks to venture capital funding from renowned specialists.

No comments yet.